haematology
Medicine

AF and diabetes: DOAC better than warfarin for cardiac and limb events


Rivaroxaban is associated with fewer major adverse cardiac events (MACE) and major adverse limb events (MALE) than warfarin in patients with non-valvular atrial fibrillation and comorbid type 2 diabetes, a study shows. A retrospective claims analysis in the US of more than 10,000 patients on rivaroxaban and almost 14,000 warfarin users found rivaroxaban was associated ...

Already a member?

Enter your email to keep reading.


OR